-
Leveraging Hot Melt Extrusion for Solubility and Continuous Manufacturing
Hot melt extrusion (HME) technology leads to enhanced solubility.
PAP-Q2-18-CL-007 -
Inside Mergers & Acquisitions
Innovation and efficiency are both key to successful drug development and commercialization.
PAP-Q2-18-CL-001 -
Changes in the Biopharma Industry: from Minor to Major Evolution
The biopharmaceutical industry continues to grow rapidly. Targeted biologics are helping treat previously untreatable diseases.
PAP-Q2-18-NI-002 -
Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile
The clinical trial paradigm has shifted.
PAP-Q2-18-CL-002 -
Taking Middle-Market CROs and CDMOs to the Next Level
Smaller outsourcing organizations often need assistance moving to the next level.
PAP-Q2-18-CL-003 -
Addressing Development Challenges for Complex Biologic Drug Candidates
Biotherapeutics identified as potential drug candidates are increasingly complex.
PAP-Q2-18-CL-004 -
Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence
Next-generation viral vector and gene therapy manufacturing facilities must be flexible.
PAP-Q2-18-CL-005 -
Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network
As biologic drugs become more complex and sophisticated, biopharmaceutical companies increasingly need the support of contract development and manufacturing organizations (CDMOs) with advanced capabilities and technology platforms that are consistently implemented across scales and geographies.
PAP-Q2-18-CL-006 -
Building a Biologics Business from the Ground Up
Building a biologics business from the ground up provides tremendous flexibility but requires the right business strategy.
PAP-Q2-18-CL-008 -
Using a Risk-Based Approach to Manufacturing in a Multi-Product Facility
Manufacturing in multi-product facilities affords numerous advantages- and challenges.
PAP-Q2-18-CL-009 -
State-of-the-Art Biologics Manufacturing in an Unexpected Location
Biotechpharma UAB, located in Vilnius, is exporting biologic drug substances worldwide.
PAP-Q2-18-CL-010 -
Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing
Viral vector manufacturers involved in all stages of clinical-trial-material and commercial product production rely on single-use (SU) technologies.
PAP-Q2-18-CL-011 -
Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance
Oral solid dosage (OSD) remains the preferred dosage delivery form for the formulation of many of today’s drug products.
PAP-Q2-18-CL-012 -
Strengthening the Outsource Service Offering through Integration
Controlling costs and increasing efficiencies are two fundamental drivers for outsourcing of pharmaceutical manufacturing.
PAP-Q2-18-CL-013 -
Corporate Social Responsibility as a Driver for Improved Sustainability
The pharmaceutical industry must respond to growing expectations regarding the environmental impact of medicinal products and manufacturing.
PAP-Q2-18-CL-014 -
Challenges for Next-Generation Biological Therapeutics Discovery and Development
In the last three and half decades, the focus of drug discovery and development has gradually shifted to large, complex molecular entities — therapeutic biologics.
PAP-Q2-18-FA-001 -
Thinking a Generation Ahead: Biologics-Based Therapy
Whether dealing with stem cells, CRISPR Cas-9 technology or antibody-drug conjugates, there is no shortage of innovation - the challenge is scaling up.
PAP-Q2-18-FA-002 -
Finishing Touches – The Future of Fill-Finish and Pharma Packaging
Fill-finish has remained relatively stable in spite of myriad developments in the industry over the last decade.
PAP-Q2-18-FA-003 -
Maximizing ROI through Equipment Liquidation
Cost pressures are significant drivers for pharmaceutical manufacturers seeking to eliminate redundancies and increase productivity and efficiency.
PAP-Q2-18-CL-015 -
Experience Meets Flexibility
Advances in rapid synthesis technologies are leading to the preparation of new classes of compounds with attractive therapeutic properties.
PAP-Q2-18-CL-016 -
Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing
Most often developed as injectable formulations, a few “oral peptide” drugs have been approved in recent years.
PAP-Q2-18-CL-017 -
Achieving Controlled Nucleation During Aseptic Lyophilization
Controlled nucleation is essential for obtaining high-quality lyophilized products with intra- and inter-batch consistency.
PAP-Q2-18-CL-018 -
BioPharma CDMO Success Requires Technical Leadership and Problem-Solving Capabilities
Since their introduction, biologic drugs have shown great potential to treat diseases not possible to remedy with traditional small-molecule drugs.
PAP-Q2-18-CL-019 -
Providing Flexible Capabilities to Meet Market Demand for Sterile Fill-Finish Services
The fill-finish step in the manufacturing of drugs is the last step completed before a product is packaged and delivered to the patient.
PAP-Q2-18-CL-020 -
DOPING – Famous Cases, Substances and Values in Sports
Doping remains a constant threat to the ethics and values in professional sports, as well as on the amateur level.
PAP-Q2-18-NI-003
-
Building a Robust Supply Chain with Dependable Quality Primary Suppliers
Drug manufacturers and their suppliers face a number of challenges, such as downward pricing pressures and the need for flexibility and speed to market, says Dale Martin, General Manager & CFO for CapsCanada.
-
With Expertise Comes Security
Using a trusted expert to remove surplus equipment helps protect your facility and assets, says Matt Hicks, Chief Operating Officer & Counsel for Federal Equipment Company.
-
Death to Cleanrooms in Biopharmaceutical Manufacturing
Marc Pelletier, Ph.D., Director of CRB USA explains the benefits of closed processing.
-
Biosimilars: Are We on the Edge of a New Era of Biologics?
Experts weigh in on our Roundtable question.
-
Nice Insight Overview: The Key to Pharma’s Next Generation Success
Evolving markets are prompting drug owners and developers to pursue new business models in the post-blockbuster era.
-
Behind the Scenes of International Pharmaceutical Business Success: A Conversation with Horst Wallrabe
Haig Armaghanian is in conversation with Horst Wallrabe, formerly of Bayer, to reflect on his impressive career and what lies ahead.
-
Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
The company received approval to relocate existing immunodiagnostic manufacturing operations to a new Consolidated Manufacturing Facility (CMF) in Emeryville, California.
-
Xolair Gets Breakthrough Therapy Designation from US FDA for Treatment of Food Allergies
If approved, the drug would be the first FDA-approved treatment for the prevention of severe reactions due to food allergies.
-
Perrigo to Divest Its Prescription Drug Business
Company to focus on generics and consumer products.
-
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
The designation is based on Phase 3 BEACON CRC safety lead-in data.
-
Focused on Fermentation
Capua BioServices continues to invest to support modern fermentation, explains Elise Mous Director Sales & Marketing/Business Development and Thomas De Maria, Business Development Manager.
-
Why Business Continuity Management is Important for CDMOs
Mayeul Cauvin, Risk Management Department, Corporate Loss Prevention Manager for Servier CDMO explains the impact of Business Continuity Management.
-
Supporting the Tech Transfer Continuum for Cell & Gene Therapies
Thought leaders from Brammer Bio explain how to satisfy development and manufacturing needs of next generation therapies.
-
Making Real-Time Process Analytical Technology In Biomanufacturing A Reality
Clint Pepper, Ph.D., Director of MAST Technology at Capsugel, explains the Modular Automated Sampling Technology platform.
-
New Ventures in the Microbiome
Predictions look bright for the microbiome market.
-
Changes in the Biopharma Industry: from Minor to Major Evolution
Real-world evidence and digital technologies are creating new medical solutions that will change the way diseases are detected, treated and prevented.
-
China to Accelerate Review of 48 Foreign Drugs
China’s FDA publishes a list of drugs approved in the US, EU and Japan needed in the country.
-
Artios Pharma Receives $84 million in Series B Funding
The DNA Damage Response (DDR) company is developing innovative treatments for cancer.
-
Mallinckrodt Forms Collaborative Research Partnership with Washington University in St. Louis
Mallinckrodt to fund up to $10 million in collaborative research programs over five years to focus on rare diseases.
-
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
Alteogen Inc. has received an approval for orphan drug designation from the US Food and Drug Administration (FDA) with one of its assets (ALT-P7) for gastric cancer.
THE ROAD TO BIO: THE EXTENDED STORY
View AllRoad To BIO: Coming Soon To Your Screen Q4 2018
The Road to BIO in Review
The Road To BIO: Day 12 California
The Road To BIO: Day 11 Arizona /// California
The Road To BIO: Day 10 Texas /// Arizona
The Road To BIO: Day 9 Texas
The Road To BIO: Day 8 Texas
The Road To BIO: Day 7 Mississippi /// Texas
The Road To BIO: Day 6 Georgia /// Mississippi
The Road To BIO: Day 5 South Carolina /// Georgia
The Road To BIO: Day 4 Tennessee /// South Carolina
The Road To BIO: Day 3 Pennsylvania /// Tennessee
The Road To BIO: Day 2 New York /// Pennsylvania
The full story of this epic journey can be experienced as an audiobook. Listen to the story behind the story – the characters, the challenges, and all 12 days of the Road To BIO.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestXolair Gets Breakthrough Therapy Designation from US FDA for Treatment of Food Allergies
Aug 14, 2018 12:13:08 PM PAO-M08-18-NI-016Forces Driving Growth in the U.S. Surgical Microscopes Market
Aug 9, 2018 3:58:58 PM PAO-08-18-CL-001Intertek Groups Expands Offerings with the Acquisition of Alchemy Systems
Aug 9, 2018 1:12:27 PM PAO-M08-18-NI-012New Method Developed for Stereoselective Synthesis of Biologic Drug Substances
Aug 8, 2018 2:11:08 PM PAO-M08-18-NI-011New Collaboration Targets Drug Development Using the Gut Microbiome
Aug 7, 2018 3:12:17 PM PAO-M08-18-NI-007
TOPICS
View All TopicsPRESS RELEASES
View AllNice Insight Industry Benchmark Reports 2017
Download Sample Report
